Identification of an endogenous peptide-ligand for the benzodiazepine receptor

An inhibitor of ³H-diazepam binding with characteristics that distinguish it from the other endogenous ligands reported for the benzodiazepine receptor was obtained from bovine brain. After isolation by gel filtration and ion exchange chromatography, the inhibitory factor was found to be a weakly charged molecule of approximately 3000 daltons. Although heat stable, the activity of the factor can be destroyed by treatment with papain. This factor, presumably peptide in nature, inhibited ³H-diazepam binding competitively and in a concentration dependent fashion.     

Endogenous regulators of benzodiazepine recognition sites

The method used to prepare crude synaptic membranes (CSMs) from rat brain affects the results obtained for the binding characteristics of ³H-diazepam and the GABA-induced stimulation of ³H-diazepam to CSM. In freshly prepared membranes (rich in GABA and other endogenous inhibitory factors), the K_D for ³H-diazepam is approximately 10 nM and the threshold dose of GABA needed to stimulate this binding is approximately 10^?5M. Removal of GABA resulted in an increase in the K_D values for ³H-diazepam binding. In contrast removal of endogenous inhibitory factors (by treatment of the membranes with Triton X-100) resulted in a decrease of the K_D values. In the Tritron X-100 treated membranes the threshold dose of GABA (10^?8M) required to stimulate ³H-diazepam binding is in the range of the high affinity component of ³H-GABA binding. Addition of crude preparations of endogenous inhibitor to these membranes increased the K_D of ³H-diazepam and inhibited the GABA-induced stimulation of ³H-diazepam binding.     

Decreased 3H-diazepam binding is a specific response to chronic benzodiazepine treatment.

Specific ³H-diazepam binding was measured in rat cortex after 7–10 days of twice daily treatment with large doses of either flurazepam or barbital. Subjective ratings of drug response each day showed that barbital treated rats experienced a degree of ataxia equal to, or greater than, that experienced by the benzodiazepine treated animals. Before performing the binding assay, the membrane preparation was washed 3 times in hypotonic buffer to remove aby residual drug. Flurazepam treatment caused a 16% decrease in maximal ³H-diazepam binding, but no change in binding affinity, confirming previous results. In contrast, barbital treatment caused no change in either binding affinity or in maximal binding. Thus, decreased diazepam binding appears to be a specific response to prolonged receptor occupation, and not part of a more generalized adaptation to chronic CNS depression.     

Evidence that benzodiazepine receptors reside on cerebellar purkinje cells: Studies with “nervous” mutant mice

The age-related, regionally-specific loss of ³H-diazepam binding sites in nervous mutant mice paralleled the loss of cerebellar Purkinje cells. These results suggest that benzodiazepine receptors reside on cerebellar Purkinje cells.     

Antagonism of benzodiazepine binding in rat and human brain by Antilirium.

Physostigmine (Antilirium^R) has been reported to reverse benzodiazepine- induced sleep or coma in man and prevent death in animals. Accordingly, we investigated the effect of Antilirium upon benzodiazepine binding to both rat and human brain. We report that Antilirium inhibits ³H-diazepam and ³H-flunitrazepam binding in a dose-dependent manner. The degree of inhibition of binding by Antilirium correlates with the affinity of benzodiazepine for its “receptor” such that diazepam is more affected than flunitrazepam. The inhibition is rapid but the kinetics are complex with only doses of Antilirium showing competitive inhibition when studied at equilibrium. These results may explain, at least in part, the effectiveness of Antilirium at reversing benzodiazepine-induced hypnosis without necessarily implicating a cholinergic mechanism.     

Etomidate stereospecifically stimulates forebrain,but not cerebellar, 3H-diazepam binding

³H-Diazepam binding to a total particulate fraction of rat forebrain is enhanced by (+)-etomidate and GABA, but not by (?)-etomidate. The enhancement of ³H-diazepam binding by (+)-etomidate was due to a two-fold increase in binding affinity, the maximal number of sites remained unchanged. The degree of stimulation with (+)-etomidate was higher than that obtained with GABA. THIP did not stimulate ³H-diazepam binding to forebrain, and did not reverse the enhanced binding seen with (+)-etomidate or GABA. In a synaptosomal membrane preparation of rat cerebellum, unlike (+)-etomidate, GABA and muscimol produced a marked stimulation of ³H-diazepam binding. (+)-Etomidate did not inhibit ³-muscimol binding to GABA receptors, nor did it activate or inhibit other $\text{in vitro}$ receptor binding assays. The effects of (+)-etomidate on the benzodiazepine binding are different from those of gabamimetic drugs. It is proposed that like barbiturates, (+)-etomidate may affect benzodiazepine binding by interaction with the chloride ionophore which is coupled to the GABA-receptor.     

Reduced diazepam binding following chronic benzodiazepine treatment.

Specific ³H-diazepam binding was measured in rat cortex after 7–10 days of twice daily injection of a large dose of flurazepam. Compared to cortex taken from saline treated controls, there was a statistically significant decrease of about 15% in the maximum binding capacity (B_max). There was also a change in the dissociation constant (K_D) from 5.27 to 8.80 nM. Repeated washing of the tissue sample before the binding assay showed that the B_max was truly decreased in the treated animals, but the change in K_D was probably an artifact due to residual flurazepam remaining in the tissue that interfered with the binding assay. It is concluded that chronic benzodiazepine treatment caused an apparent decrease in the number of specific binding sites.     

Effect of striatum tissue transplantation on behavioral functions and state of benzodiaze-pine receptors in rats with lesioned amygdala

The effects of grafted embryonic striatum tissue on the state of benzodiazepine system (BDS) (assessed by the level of³H-diazepam binding with synaptic membranes) and on behavior of animals with lesioned left amygdala in open field have been studied in rats. The injury of amygdala by either kainic acid application or saline injection produced a disbalance between inhibitory and excitatory transmitters. As a result, the level of³H-diazepam binding decreased as compared with that in intact animals, thus demonstrating attenuation of GABA-ergic inhibitory transmission by the BDS. Rats with lesioned amygdala showed disturbance in some behavioral functions. Transplantation normalized the behavior and increased the level of³H-diazepam binding.     

Changes in mouse brain diazepam receptor binding after phenobarbital administration

Specific ³H-diazepam binding was measured $\text{in vitro}$ in adult mouse (strain, Crl=CD-1) brain after four days of an inductive dose of phenobarbital pretreatment (i.p.). Sexual dimorphism was observed in ³H-diazepam brain binding, female mice had significantly higher benzodiazepine binding than males without any differences in apparent affinity constants (K_D). Phenobarbital pretreatment caused a significant decrease in the maximal number of binding sites (Bmax) as well as in dissociation rate constants in both sexes.     

Affinity of 3-oxyphenazepam esters for benzodiazepine receptors

A metabolite of the anxiolytic, anticonvulsant, and soporific drug phenazepam, 3-oxyphenazepam (3-OPh), possesses strong anxiolytic action. In the present work, 3-OPh and its acetic, benzoic, nicotinic, hemisuccinic, hemiglutaric, and valproic esters were synthesized, and their interaction with benzodiazepine receptors of the rat central nervous system was investigated. The structure of the compounds is found to correlate with their affinity to benzodiazepine receptors (inhibition constants characterizing specific binding of³H-diazepam with the P fraction of synaptic membranes in the rat brain), as well as with their anxiolytic activities. The affinities of dicarbonic acid monoesters (hemisuccinate and, especially, hemiglutarate) and valproate were found to be lower than those of monocarbonic acid esters and 3-OPh itself. High pharmacological activity of 3-OPh hemisuccinate is hypothesized to be determined by its role as a 3-OPh precursor (the latter is a product of hemisuccinate hydrolysis).Neirofiziologiya/Neurophysiology, Vol. 26, No. 4, pp. 262–265, July–August, 1994.     

No changes in rat benzodiazepine receptors after withdrawal from continuous treatment with lorazepam and diazepam.

Five and 11 days after withdrawal from 8 weeks of treatment with 90 mg/kg/day of diazepam p.o. or 60 mg/kg/day of lorazepam p.o. there were no consistent changes in the number of benzodiazepine receptors or apparent affinity $\text{in vitro}$ for ³H-diazepam at 0°C in rat forebrain membranes. Daily exposure of rats from 10 days before birth until 7 days after birth was also without gross effects on the benzodiazepine receptor. Abstinence and tolerance to benzodiazepines were thus not attributable to changes in brain benzodiazepine receptors.     

Gaba stimulation of 3H-diazepam binding in aged mice

Specific ³H-diazepam binding to washed brain membranes from C57BL/6 mice of different age groups (3, 6, 12, 24 and 36 months) was studied in the absence and presence of 30 μM GABA. GABA treatment was found to be effective in decreasing the K_D of ³H-diazepam binding of approximately 50% in all age groups tested (mean control K_D = 6.5 nM, mean GABA-treated K_D = 3.2 nM). No significant changes with age were observed in benzodiazepine receptor K_D or B_max in the presence or absence of GABA.     

Aging and benzodiazepine binding in the rat cerebral cortex

The specific binding of ³H-diazepam in the cerebral cortex was investigated in membrane preparations from 6 and 30 month old Fischer-344 rats. No age-related differences in the association, equilibrium, or dissociation binding characteristics were observed. The increased sensitivity of the elderly to the central sedative effects of the benzodiazepines does not, therefore, appear to involve changes in binding to the receptor site located in the cortex.     

Coexistence of central and peripheral benzodiazepine binding sites in the human pineal gland

The pineal gland and particularly its major hormone, melatonin, may participate in several physiological functions, including sleep promotion, anticonvulsant activity and the modulation of biological rhythms and affective disorders. These effects may be related to an interaction with benzodiazepine receptors, which have been demonstrated to be present in the pineal gland of several species including man. The present study examined the characteristics of benzodiazepine binding site subtypes in the human pineal gland, using [³H] flunitrazepam and [³H] PK 11195 as specific ligands for central and peripheral type benzodiazepine binding sites respectively. Scatchard analysis of [³H] flunitrazepam binding to pineal membrane preparations was linear, indicating the presence of a single population of sites. Clonazepam and RO 15-1788, which have a high affinity for central benzodiazepine binding sites, were potent competitors for [³H] flunitrazepam binding in the human pineal, whereas RO 5-4864 had a low affinity for these sites. Analyses of [³H] PK 11195 binding to pineal membranes also revealed the presence of a single population of sites. RO 5-4864, a specific ligand for peripheral benzodiazepine binding sites was the most potent of the drugs tested in displacing [³H] PK 11195, whereas clonazepam and RO 15-1788 were weak inhibitors of [³H] PK 11195 binding to pineal membranes. Overall, these results demonstrate, for the first time, the coexistence of peripheral and central benzodiazepine binding sites in the human pineal gland.     

Effect of some potent adenosine uptake inhibitors on benzodiazepine binding in the CNS

A series of nucleoside transport inhibitors has been tested for their ability to displace [³H]diazepam binding to CNS membranes. No correlation between their potency as [³H]adenosine uptake blockers and as inhibitors of [³H]diazepam binding was found, either in rat or guinea-pig brain tissue. Dipyridamole, a potent adenosine transport inhibitor interacted strongly (K_i = 54 nM) with peripheral-type benzodiazepine binding sites (“acceptor sites”) and was 4–5 fold weaker in displacing [³H]methylclonazepam and [³H]Ro15-1788, ligands selective for the specific central benzodiazepine “receptor”. Unlike the benzodiazepines, dipyridamole had no anticonvulsant action against metrazole-induced convulsions in mice. Ro5-4864, a benzodiazepine which selectively interacts with the peripheral-type benzodiazepine binding site, was approximately equipotent with diazepam in inhibiting [³H]adenosine uptake in brain tissue. These results do not support the idea of a very close link between high-affinity central binding sites for clinically-active benzodiazepines and the adenosine uptake site. The possibility of a connection between benzodiazepine “acceptor” sites and the membrane nucleoside transporter is discussed.     

Amygdala kindled seizure stage is related to altered benzodiazepine binding site density

Benzodiazepine receptor binding was examined in rats at 3 stages of amygdaloid kindling (i.e., initial afterdischarge, Stage 3 and Stage 5) immediately or 24 hr after seizure. 3H-diazepam binding site density (Bmax) was significantly increased 24 hr after Stage 3 and Stage 5 kindled seizures in the hippocampus but not in the amygdala. There were no significant differences in the dissociation constants (KD) between kindled and control rats at any time point examined for either brain region. These results demonstrate that changes in benzodiazepine binding are observed with partial kindled seizures (i.e., Stage 3), indicating that generalized seizures are not prerequisite to increased benzodiazepine receptor site density.     

Effect of picrotoxinin on benzodiazepine receptor binding

The effect of picrotoxinin on [³H]flunitrazepam binding to benzodiazepine receptors was investigated. In mouse forebrain membranes, picrotoxinin inhibited basal, GABA- and pentobarbital-stimulated [³H]flunitrazepam binding; this inhibitory activity was temperature- and chloride ion-dependent. Scatchard analysis of the data indicates that picrotoxinin decreases the number of binding sites without alterating binding affinity. In cerebellar membranes, picrotoxinin did not alter [³H]flunitrazepam receptor binding.     

Melatonin reverses pinealectomy-induced decrease of benzodiazepine binding in rat cerebral cortex

Pinealectomy of rats resulted in significant depression of benzodiazepine receptors (assessed by [³H]flunitrazepam binding) in cerebral cortex 3–14 days after surgery without affecting their affinity significantly. A single s.c. injection of melatonin (800 μg/kg body wt) restored the depressed brain benzodiazepine receptor sites. Single melatonin injections (up to 1600 μg/kg) to intact rats did not affect brain benzodiazepine binding when injected at either morning or evening hours. Daily melatonin treatment to intact rats for 5 days augmented benzodiazepine receptor density in brain (morning injections) or its dissociation constant (evening injections). Melatonin added in vitro to rat cerebral cortex membranes only slightly depressed [³H]flunitrazepam binding at 100 μM concentrations. These results point out a link between pineal activity and benzodiazepine receptor function in rats. They also indicate that pharmacological doses of melatonin affect benzodiazepine binding sites in rat cerebral cortex.     

Brain benzodiazepine receptors increase after chronic ethyl-β-carboline-3-carboxylate

Rats were treated with repeated intraventricular injections of ethyl-3-carboline-3-carboxylate (β-CCE) (10 ug/rat, twice daily for 8 days), 36 h after the last injection, the total number of H-diazepam binding sites was increased in the cerebral cortex, cerebellum and hippocampus by 63, 51 and 38%, respectively. On the other hand, there were no significant differences in the dissociation constants (K_D) between β-CCE and solvent treated rats. In contrast, chronic β-CCE administration failed to change the number of the apparent affinity of H-β-CCE binding sites in all the brain areas examined. The results suggest that β-CCE is an antagonist at the ³H- diazepam binding sites.     

The characteristics of higher nervous activity and of the brain benzodiazepine system in rats subjected to ethanol exposure in the prenatal period

Exposure to ethanol during pregnancy results in the alternation of 3H-diazepam binding to synaptosomal neocortical membranes from the rat offspring. In male experimental rats, 14 days of age, binding level diminished to 11%. In two-month-old control rats Scatchard plot was biphasic. It has been shown that prenatal exposure to ethanol leads to changes in the nature of binding in two-month-age experimental animals, as compared with the control ones. 3H-diazepam binding changes went along with behavioural deviations. In experimental rats locomotor activity was increased in the "open field" test, passive avoidance conditioned reflex retention was decreased and elaboration parameters of active avoidance conditioned reflex were changed, as compared with the control ones. The data obtained show that higher integrative functions were disturbed by prenatal alcoholization. Correlations between benzodiazepine receptor state and behaviour were studied.